Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With TTX-381 for the Ocular Manifestations Associated With Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) Disease

NCT05791864 is registered in ClinicalTrials.gov with Tern Therapeutics, LLC as lead sponsor.

NCT NCT05791864
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05791864 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With TTX-381 for the Ocular Manifestations Associated With Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) Disease
Lead sponsor
Tern Therapeutics, LLC
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 17, 2023
Completion date
December 31, 2031
Enrollment
26 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

neuronal ceroid lipofuscinosis type 2